Tumor Biology

, Volume 36, Issue 11, pp 8275–8276 | Cite as

Letter regarding “CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis” by Zhang et al.

Commentary

Keywords

FAS Genetic variation Meta-analysis Risk Uterine cervical neoplasms 

Notes

Acknowledgments

The author’s work in this area has been supported by the Research University Grant of Universiti Sains Malaysia (No. 1001/PPSP/812109).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Zhang Y, Tong S, Guan L, Na F, Zhao W, Wei L. CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis. Tumour Biol. 2014;35(3):1785–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Shen J, Sun NX. Association between FAS A670G polymorphism and susceptibility to cervical cancer: evidence from a meta-analysis. Tumour Biol. 2013;34(6):3443–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes. 2009;2:238.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 2005;15 Suppl 3:282–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 2003;103(2):221–5.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Human Genome Centre, School of Medical Sciences, Health CampusUniversiti Sains MalaysiaKubang KerianMalaysia

Personalised recommendations